Technical Analysis for CTMX - CytomX Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.60 | -1.84% | -0.03 |
CTMX closed down 1.84 percent on Thursday, April 25, 2024, on 26 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Flat | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -1.84% | |
| Wide Bands | Range Expansion | -1.84% | |
| Oversold Stochastic | Weakness | -1.84% | |
| Lower Bollinger Band Walk | Weakness | -4.76% | |
| Wide Bands | Range Expansion | -4.76% |
| Alert | Time |
|---|---|
| Possible NR7 | about 12 hours ago |
| Down 3% | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 14 hours ago |
| Down 2 % | about 16 hours ago |
| 200 DMA Support | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Compugen Monoclonal Antibody Therapy Immunogen Oncology Focused Biopharmaceutical
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Compugen Monoclonal Antibody Therapy Immunogen Oncology Focused Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.855 |
| 52 Week Low | 1.04 |
| Average Volume | 1,107,899 |
| 200-Day Moving Average | 1.60 |
| 50-Day Moving Average | 2.04 |
| 20-Day Moving Average | 1.94 |
| 10-Day Moving Average | 1.77 |
| Average True Range | 0.13 |
| RSI (14) | 27.54 |
| ADX | 26.79 |
| +DI | 13.92 |
| -DI | 37.16 |
| Chandelier Exit (Long, 3 ATRs) | 1.92 |
| Chandelier Exit (Short, 3 ATRs) | 1.96 |
| Upper Bollinger Bands | 2.35 |
| Lower Bollinger Band | 1.53 |
| Percent B (%b) | 0.09 |
| BandWidth | 42.75 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0463 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.69 | ||||
| Resistance 3 (R3) | 1.69 | 1.67 | 1.68 | ||
| Resistance 2 (R2) | 1.67 | 1.64 | 1.67 | 1.67 | |
| Resistance 1 (R1) | 1.63 | 1.63 | 1.62 | 1.63 | 1.66 |
| Pivot Point | 1.61 | 1.61 | 1.60 | 1.61 | 1.61 |
| Support 1 (S1) | 1.57 | 1.58 | 1.56 | 1.57 | 1.54 |
| Support 2 (S2) | 1.55 | 1.57 | 1.55 | 1.53 | |
| Support 3 (S3) | 1.51 | 1.55 | 1.53 | ||
| Support 4 (S4) | 1.51 |
